239 related articles for article (PubMed ID: 29519924)
1. Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma.
Otsuki T; Nakashima T; Hamada H; Takayama Y; Akita S; Masuda T; Horimasu Y; Miyamoto S; Iwamoto H; Fujitaka K; Miyata Y; Miyake M; Kohno N; Okada M; Hattori N
Eur Respir J; 2018 May; 51(5):. PubMed ID: 29519924
[TBL] [Abstract][Full Text] [Related]
2. MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model.
Akita S; Hattori N; Masuda T; Horimasu Y; Nakashima T; Iwamoto H; Fujitaka K; Miyake M; Kohno N
Cancer Sci; 2015 Jul; 106(7):921-8. PubMed ID: 25950387
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic efficacy of anti vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Li Q; Yano S; Ogino H; Wang W; Uehara H; Nishioka Y; Sone S
Clin Cancer Res; 2007 Oct; 13(19):5918-25. PubMed ID: 17908988
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma.
Li Q; Wang W; Machino Y; Yamada T; Kita K; Oshima M; Sekido Y; Tsuchiya M; Suzuki Y; Nan-Ya K; Iida S; Nakamura K; Iwakiri S; Itoi K; Yano S
Cancer Sci; 2015 Jan; 106(1):102-7. PubMed ID: 25421609
[TBL] [Abstract][Full Text] [Related]
5. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
[TBL] [Abstract][Full Text] [Related]
6. E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles.
Ikuta K; Yano S; Trung VT; Hanibuchi M; Goto H; Li Q; Wang W; Yamada T; Ogino H; Kakiuchi S; Uehara H; Sekido Y; Uenaka T; Nishioka Y; Sone S
Clin Cancer Res; 2009 Dec; 15(23):7229-37. PubMed ID: 19934291
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PAI-1 Limits Tumor Angiogenesis Regardless of Angiogenic Stimuli in Malignant Pleural Mesothelioma.
Takayama Y; Hattori N; Hamada H; Masuda T; Omori K; Akita S; Iwamoto H; Fujitaka K; Kohno N
Cancer Res; 2016 Jun; 76(11):3285-94. PubMed ID: 27197170
[TBL] [Abstract][Full Text] [Related]
9. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
Ogino H; Yano S; Kakiuchi S; Yamada T; Ikuta K; Nakataki E; Goto H; Hanibuchi M; Nishioka Y; Ryan A; Sone S
Cancer Lett; 2008 Jun; 265(1):55-66. PubMed ID: 18364248
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapies for malignant pleural mesothelioma.
Yano S; Li Q; Wang W; Yamada T; Takeuchi S; Nakataki E; Ogino H; Goto H; Nishioka Y; Sone S
Front Biosci (Landmark Ed); 2011 Jan; 16(2):740-8. PubMed ID: 21196199
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth
Laszlo V; Valko Z; Kovacs I; Ozsvar J; Hoda MA; Klikovits T; Lakatos D; Czirok A; Garay T; Stiglbauer A; Helbich TH; Gröger M; Tovari J; Klepetko W; Pirker C; Grusch M; Berger W; Hilberg F; Hegedus B; Dome B
Clin Cancer Res; 2018 Aug; 24(15):3729-3740. PubMed ID: 29724868
[No Abstract] [Full Text] [Related]
12. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer.
Hashida H; Takabayashi A; Kanai M; Adachi M; Kondo K; Kohno N; Yamaoka Y; Miyake M
Gastroenterology; 2002 Feb; 122(2):376-86. PubMed ID: 11832452
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice.
Van TT; Hanibuchi M; Kakiuchi S; Sato S; Kuramoto T; Goto H; Mitsuhashi A; Nishioka Y; Akiyama S; Sone S
Cancer Chemother Pharmacol; 2011 Aug; 68(2):497-504. PubMed ID: 21079960
[TBL] [Abstract][Full Text] [Related]
14. Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
Nakataki E; Yano S; Matsumori Y; Goto H; Kakiuchi S; Muguruma H; Bando Y; Uehara H; Hamada H; Kito K; Yokoyama A; Sone S
Cancer Sci; 2006 Mar; 97(3):183-91. PubMed ID: 16542214
[TBL] [Abstract][Full Text] [Related]
15. Restored expression of the MYO18B gene suppresses orthotopic growth and the production of bloody pleural effusion by human malignant pleural mesothelioma cells in SCID mice.
Edakuni N; Ikuta K; Yano S; Nakataki E; Muguruma H; Uehara H; Tani M; Yokota J; Aizawa H; Sone S
Oncol Res; 2006; 16(5):235-43. PubMed ID: 17294804
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo.
Miyoshi S; Hamada H; Hamaguchi N; Kato A; Katayama H; Irifune K; Ito R; Miyazaki T; Okura T; Higaki J
Int J Oncol; 2012 Aug; 41(2):449-56. PubMed ID: 22580933
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma.
Moriya M; Yamada T; Tamura M; Ishikawa D; Hoda MA; Matsumoto I; Klepetko W; Oda M; Yano S; Watanabe G
Oncol Rep; 2014 Mar; 31(3):1109-15. PubMed ID: 24378576
[TBL] [Abstract][Full Text] [Related]
18. Bcl-xL antisense oligonucleotide and cisplatin combination therapy extends survival in SCID mice with established mesothelioma xenografts.
Littlejohn JE; Cao X; Miller SD; Ozvaran MK; Jupiter D; Zhang L; Rodarte C; Smythe WR
Int J Cancer; 2008 Jul; 123(1):202-8. PubMed ID: 18360826
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
Kurai J; Chikumi H; Hashimoto K; Takata M; Sako T; Yamaguchi K; Kinoshita N; Watanabe M; Touge H; Makino H; Igishi T; Hamada H; Yano S; Shimizu E
Int J Oncol; 2012 Nov; 41(5):1610-8. PubMed ID: 22922885
[TBL] [Abstract][Full Text] [Related]
20. EF24 and RAD001 potentiates the anticancer effect of platinum-based agents in human malignant pleural mesothelioma (MSTO-211H) cells and protects nonmalignant mesothelial (MET-5A) cells.
Onen HI; Yilmaz A; Alp E; Celik A; Demiroz SM; Konac E; Kurul IC; Menevse ES
Hum Exp Toxicol; 2015 Feb; 34(2):117-26. PubMed ID: 25028262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
